Article · 13 Nov 2026
ArticlePublished 2010
Second Line Therapy for Advanced Pancreatic Adenocarcinoma: Where Are We and Where Are We Going? Highlights from the
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Most patients with adenocarcinoma of the pancreas present with locally advanced or metastatic disease. Although single agent gemcitabine is widely accepted as first-line therapy, there is no current standard of care for gemcitabine-refractory patients. Common second-line chemotherapy regimens included oxaliplatin and 5-FU/leucovorin (OFF), gemcitabine and oxaliplatin (GEMOX), oxaliplatin and capecitabine (XELOX), and irinotecan-oxaliplatin. At the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, several new second-line chemotherapy regimens were presented, including gemcitabine and oxaliplatin with imatinib, single agent nab-paclitaxel, and the combination of high-dose capecitabine with oxaliplatin and sorafenib. These abstracts provide exciting new directions for the treatment of gemcitabine-refractory advanced pancreatic cancer
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of the Pancreas.
Article · 25 Jun 2026
Comparative outcomes of Open and Laparoscopic drainage in Walled off Pancreatic Necrosis
Article · 24 Feb 2026
Xanthogranulomatous Pancreatitis Showing Overlapping
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of the Pancreas
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Muhammad Wasif Saif”
- BylineArticles whose byline prints “Christina Brus”